APA (7th ed.) Citation

DE, S., T, D., RR, M., BH, L., M, F., SC, G., . . . AE, R. (2024). Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: The OPTYX study protocol. Future oncology (London, England), 20(12), 727. https://doi.org/10.2217/fon-2023-0748

Chicago Style (17th ed.) Citation

DE, Spratt, Dorff T, McKay RR, Lowentritt BH, Fallick M, Gatoulis SC, Flanders SC, and Ross AE. "Evaluating Relugolix for the Treatment of Prostate Cancer in Real-world Settings of Care: The OPTYX Study Protocol." Future Oncology (London, England) 20, no. 12 (2024): 727. https://doi.org/10.2217/fon-2023-0748.

MLA (9th ed.) Citation

DE, Spratt, et al. "Evaluating Relugolix for the Treatment of Prostate Cancer in Real-world Settings of Care: The OPTYX Study Protocol." Future Oncology (London, England), vol. 20, no. 12, 2024, p. 727, https://doi.org/10.2217/fon-2023-0748.